Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications

被引：69

作者：

Zoccolella, S

Lamberti, P

Armenise, E

de Mari, M

Lamberti, SV

Mastronardi, R

Fraddosio, A

Illiceto, G

Livrea, P

机构：

[1] Univ Bari, Osped Policlin, Dept Neurol Sci, I-70124 Bari, Italy

[2] Univ Bari, Hyg Sect, Dept Internal Med & Publ Hlth, Bari, Italy

来源：

PARKINSONISM & RELATED DISORDERS | 2005年 / 11卷 / 02期

关键词：

Parkinson's disease; homocysteine; dopamine-agonists; L-dopa; COMT-inhibitors;

D O I：

10.1016/j.parkreldis.2004.07.008

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Elevated plasma homocysteine (Hcy) concentrations have been reported in L-dopa treated Parkinson's disease (PD) patients, suggesting that L-dopa treatment is an acquired cause of hyperhomocysteinemia. Aim of this study is to evaluate the effects of different antiparkinsonian drugs on Hey concentrations. We compared Hey, B-12 and folate levels in 45 PD patients (15 treated with dopamine-agonists, 15 with L-dopa and 15 with L-dopa plus a catechol-O-methyltransferase-inhibitor (COMT-I) and in 15 controls. Analysis of data revealed that L-dopa administration significantly increases Hcy concentrations and that the addition of COMT-I effectively reduces the homocysteinemia. (c) 2004 Elsevier Ltd. All rights reserved.

引用

页码：131 / 133

页数：3

共 17 条

[1]

ALLAIN P, 1995, NEUROTOXICOLOGY, V16, P527

[2] A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].